QUANTITATIVE RISK STRATIFICATION IN MARKOV CHAINS WITH QUASI-STATIONARY DISTRIBUTIONS David C Chan, MD, MSc 1 ; Philip K Pollett, PhD 2 ; Milton C Weinstein,

Slides:



Advertisements
Similar presentations
Evaluating health informatics projects Reasons for and problems of evaluation Objective model Subjective model.
Advertisements

Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services.
Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
EVIDENCE BASED MEDICINE for Beginners
Subgroup Analysis in Cost-Effectiveness Analysis ISPOR Issues Panel May 17, 2004 Joseph Heyse John Cook Merck Research Laboratories.
Extension Article by Dr Tim Kenny
Nov M. Huang Northwestern Univ. 1 Markov Chain Population Models in Medical Decision Making Gordon Hazen Min Huang Northwestern University.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
Chapter 11: Sequential Clinical Trials Descriptive Exploratory Experimental Describe Find Cause Populations Relationships and Effect Sequential Clinical.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
S S (5.1) RTI, JAIPUR1 STATISTICAL SAMPLING Presented By RTI, JAIPUR.
Research problem, Purpose, question
BA 427 – Assurance and Attestation Services
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Epidemiology of Stroke Dexter L. Morris, PhD, MD Department of Emergency Medicine University of North Carolina School of Medicine Chapel Hill, NC.
CI-1 Update on the Safety of Erythropoietin Products in Patients With Cancer May 4, 2004 Robert DeLap, MD, PhD Vice President, Global Regulatory Affairs.
Alon Barsheshet, MD1, Paul J. Wang, MD2, Arthur J. Moss, MD1, Scott D
1 Evaluating the impact of information technology on clinician workload using time-motion methodologies Lisa P. Newmark, Carol Keohane, RN, Eric G. Poon,
1 National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004 CIHR Team Grant.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.
Value of Information Analysis Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center Los Angeles Biomedical Research Institute.
What research is Noun: The systematic investigation into and study of materials and sources in order to establish facts and reach new conclusions. Verb:
Denise F. Johnson, MPH, MBA LaShaunda L. Malone, MSPH Catherine M. Stein, PhD American Public Health Association Meeting November 5, 2013 Boston, MA. The.
Research Design. Research is based on Scientific Method Propose a hypothesis that is testable Objective observations are collected Results are analyzed.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Slides courtesy of Mark Estes, MD Role of AED’s Concept Developed 1977 Implantable cardioverter defibrillator 1979 AED developed.
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
Understanding Why Patients Accept Vaccination: A Socio-Behavioral Approach at the University of Louisville Vaccine and International Health and Travel.
Monthly Journal article review: Vimmi Kang PGY 2
Applications of IndiGO to ACOs David M Eddy MD PhD Founder and Chief Medical Officer Emeritus Archimedes San Francisco, CA ... a KAISER PERMANENTE Innovation.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
Decision making Under Risk & Uncertainty. PAWAN MADUSHANKA MADUSHAN WIJEMANNA.
Therapeutic Equivalence & Active Control Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
THE HIT ADOPTIONINITIATIVE The George Washington University School of Public Health and Health Services The Institute for Health Policy at MGH/Partners.
PHARMACOECONOMIC EVALUATIONS & METHODS MARKOV MODELING IN DECISION ANALYSIS FROM THE PHARMACOECONOMICS ON THE INTERNET ®SERIES ©Paul C Langley 2004 Maimon.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
Knowledge and experiences about health literacy needs and assessment among fourth year nursing students in Thailand Sinsakchon Aunprom-me, MPH, Ph.D. (Target.
Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,
Evaluating Persistence Times in Populations Subject to Catastrophes Ben Cairns and Phil Pollett Department of Mathematics.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
A-1 Introduction Pravastatin-Aspirin 7asdf Fred T. Fiedorek, M.D. Vice President, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute.
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
Is Veteran User Status an Independent Risk Factor for Mortality After Private Sector CABG? William B. Weeks, MD, MBA Dorothy A. Bazos, Ph.D. David M. Bott,
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Case 4: 65-year-old Man Newly Diagnosed, Has Other Health Issues Paul E. Sax, MD Clinical Director, Division of Infectious Diseases Brigham and Women’s.
Research Design Evidence Based Medicine Concepts and Glossary.
Introduction to Research for Physical Therapy Students.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Angela Aziz Donnelly April 5, 2016
Mild, moderate, and severe intensity cut-points for the Respiratory Distress Observation Scale©: A receiver operating characteristic curve analysis Margaret.
Purpose of Research Research may be broadly classified into two areas; basic and applied research. The primary purpose of basic research (as opposed to.
Ethical Principles of Research
Medication Use Pattern Mining for Childhood Pneumonia Using Six Year Inpatient Electronic Medical Records in a Shanghai Hospital, China Chunlei Tang, PhD1,2,3,
Comments on Methodological Challenges in Clinical Trials for CIPN Scott Evans, PhD, MS Harvard University ACTTION, 2017.
Regulatory perspective
Friends of Cancer Research
How EBM brings the connection between evidence and measurement into focus. Benjamin Smart.
Clinical Trials to “Real-World” Heart Failure: Applying Risk Stratification to Deliver Personalized Care  Ragavendra R. Baliga, MD, MBA  Heart Failure.
Improving the Use of Medications to Treat Complex Health Problems in Resource-Poor Settings: Community-Based Examples from Haiti and Peru Jennifer Furin,
RegionAl: an Optimized Regional Classifier to Predict Mortality in
A Population Level Analysis of Statewide Claims Data
Assessment of Breast and Colorectal Cancer Surgery in Manitoba
My PAH Patient.
Presentation transcript:

QUANTITATIVE RISK STRATIFICATION IN MARKOV CHAINS WITH QUASI-STATIONARY DISTRIBUTIONS David C Chan, MD, MSc 1 ; Philip K Pollett, PhD 2 ; Milton C Weinstein, PhD 3 1 Division of General Internal Medicine, Brigham and Women’s Hospital, Boston, MA; 2 University of Queensland, Queensland, Australia; 3 Harvard School of Public Health, Boston, MA. Contact Information: David Chan, MD, MSc Brigham & Women’s Hospital 75 Francis Street, Boston, MA (617) BACKGROUND PURPOSE METHODS RESULTS CONCLUSIONS DISCUSSION  Markov chains are frequently used to model disease processes in decision analysis.  A Markov chain in which all living patients eventually die is called a transient chain with an absorbing state (death).  Quasi-stationary distributions represent the limiting probability conditional on no absorption (the eventual probability of a surviving patient being in a certain state).  We considered a general Markov chain with N living states and an absorbing death state D.  Using Markov chain theory, we solved for the conditions under which a positive quasi- stationary distribution exists.  We considered the specific example of targeting risky heart failure patients, and we explored the use of quasi-stationary distributions to quantify risk.  In clinical practice, treatment decisions often rely on the concept of risk stratification.  The decision in these cases is not whether all patients should be treated as a group, but how many patients should be treated when the group is risk-stratified.  We considered a general Markov chain with living states L 1, …, L N and an absorbing death state D.  A unique positive quasi-stationary distribution exists for the living states, if and only if patients in L 1 are at lowest risk for progression or death.  As an example, heart failure patients with greater previous hospitalizations (H) are more likely to die or be hospitalized. A positive quasi-stationary distribution therefore exists for surviving patients.  This quasi-stationary distribution allows for quantitative risk stratification of living patients.  Outcomes for quantitatively defined populations at risk (e.g. “highest quintile”) can be evaluated.  Risk can be inferred from observed outcomes, and expected outcomes can be extrapolated from theoretical risk. L1L1 L2L2 L3L3 LNLN D · · · Quasi-stationary distributions exist in Markov chains with properties that are natural for many disease models.  Quasi-stationary distributions allow for quantitative definitions of risk within an established framework of Markov chain modeling.  Patient risk in trials can be quantitatively inferred from observed outcomes. Outcomes can then be extrapolated to populations of different risk.  Limitation: Quasi-stationary distributions do not account for population influx. Risk stratification is a necessary part of many clinical decisions. Quantitative risk stratification is made possible by quasi-stationary distributions intrinsic in many Markov chains. This allows for communication about decisions for precisely how many patients, rather than simplistic ones for all or none.